Tatva Chintan Pharma Chem Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹217 Cr +75% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
TC

Tatva Chintan Pharma Chem Ltd

Q1 FY27Chemicals & Petrochemicals

Tatva Chintan Pharma Chem Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹167Cr
+42.7% YoY
+24.6% QoQ
Net profit
₹16Cr
+128.6% YoY
+60% QoQ
Margin
19%
+4 pp YoY
−2 pp QoQ

What the Q1 FY27 call signalled

2 of 3 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned
Price₹1,744
Market cap₹4.1K Cr
P/E79.0

The short version

Tatva Chintan expects a revenue CAGR of 20-25% over the next 3-4 years driven by new and existing products. Tatva Chintan expects a 20% to 25% compounded annual growth rate (CAGR) in revenue over the next 3 to 4 years.

From Tatva Chintan Pharma Chem Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Good growth
  • Tatva Chintan expects a revenue CAGR of 20-25% over the next 3-4 years driven by new and existing products.
  • Q1 FY27 saw a 43% year-on-year revenue growth and 25% sequential increase, indicating strong momentum.
  • Phase Transfer Catalysts and Structure Directing Agents (SDA) segments show robust demand expansion, supported by Euro 7 implementation and wider market acceptance.
  • Electrolyte Salts segment is expected to contribute around 10% of revenue in FY27, with gradual ramp-up driven by hybrid vehicle battery commercialization post-2026.
  • The company plans a greenfield capacity expansion to boost future revenue potential by INR300 crores at peak utilization.

2 more points from Tatva Chintan Pharma Chem Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Tatva Chintan has a planned greenfield capex of INR 200 crores for FY27 aimed at scaling up R&D-ready products and catering to domestic demand.
  • The new multiproduct facility will support pharma and agro intermediates, electrolytes, SDA, and other sectors, with an expected peak revenue of around INR 300 crores.
  • This facility is planned to be operational within 18 to 21 months, addressing expected growth beyond INR 800-850 crores revenue.
  • The company is also focusing on debottlenecking and continuous flow chemistry upgrades in existing plants to optimize capacity.

2 more points from Tatva Chintan Pharma Chem Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Tatva Chintan does not maintain a traditional order book with confirmed orders.
  • Orders are generally received and fulfilled on a quarter-on-quarter basis.
  • Customer demand is described as very visible and highly clear.

2 more points from Tatva Chintan Pharma Chem Ltd's call on order book

Create a free account to keep reading this call

Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Tatva Chintan Pharma Chem Ltd Q1 FY27 results — key figures

Tatva Chintan Pharma Chem Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue167117+42.7%134+24.6%
Operating profit (EBITDA)3217+88.2%28+14.3%
Operating margin19%15%+4 pp21%-2 pp
Profit before tax219+133.3%17+23.5%
Net profit (PAT)167+128.6%10+60%
EPS (₹)6.832.84+140.5%4.41+54.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Alufluoride (Q1 FY27)

    Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr

  • POCL Enterprises (Q1 FY27)

    466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto

  • Devson Catalyst (Q1 FY27)

    FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee

  • Ambani Orgochem (Q1 FY27)

    Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Tatva Chintan Pharma Chem Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Tatva Chintan Pharma Chem Ltd Q1 FY27 results?

Tatva Chintan expects a revenue CAGR of 20-25% over the next 3-4 years driven by new and existing products. Tatva Chintan expects a 20% to 25% compounded annual growth rate (CAGR) in revenue over the next 3 to 4 years.

What is Tatva Chintan Pharma Chem Ltd share price analysis?

Tatva Chintan Pharma Chem Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 79.0 with a market cap of ₹4,141 Cr. Investors should review the full earnings analysis for detailed insights.

Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?

Tatva Chintan has a planned greenfield capex of INR 200 crores for FY27 aimed at scaling up R&D-ready products and catering to domestic demand.

Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.